Studies are in progress on pI3K/Akt/m-TOR pathway being treated as a therapeutic target in endometrial carcinoma with m-TOR, PI3K, dual PI3K/m-TOR and Akt inhibitors [83, 84], and also, inhibition of the IL-6 receptor and its downstream effectors JAK1 (ruxolitinib) and STAT3 (nifuroxazide) are being investigated for its effect on tumour cell growth in vivo and in vitro studies [85]. Here, JAK1 is linked to neoplasm.